Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GlaxoSmithKline. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

FY2019-2023 figures are as at 30/09/2019

All figures shown are on an Adjusted basis unless stated. 
 

Please select...
£m (unless stated) 2019 2020 2021 2022 2023 2019-2023 n=
Turnover 33,295 35,748 37,073 38,636 40,212 12
Cost of sales (9,866) (10,554) (10,863) (11,226) (11,589) 12
Selling, general and administration (10,336) (10,989) (11,209) (11,489) (11,810) 12
Research and Development (4,422) (4,776) (4,963) (5,122) (5,296) 12
Royalty income 301 301 299 290 284 12
Operating profit 8,972 9,729 10,337 11,089 11,801 12
Net finance costs (903) (913) (863) (827) (793) 12
Associates 61 21 20 20 20 12
Profit before tax 8,130 8,837 9,494 10,282 11,028 12
Taxation (1,536) (1,685) (1,812) (1,963) (2,105) 12
Profit after tax  6,594 7,152 7,682 8,319 8,923 12
Minority interests* (717) (1,177) (1,272) (1,361) (1,418) 12
Profit attributable to shareholders 5,877 5,975 6,411 6,958 7,504 12
WANS (m) 4,942 4,962 4,982 5,003 5,024 12
Earnings per share (p) 118.9 120.4 128.7 139.1 149.4 12
Dividend per share (p) 80.0 80.0 80.4 81.5 82.7 11
Free Cash Flow 3,058 4,550 5,261 5,868 6,444 9
Net Debt (25,865) (23,984) (22,761) (20,938) (19,162) 11

*All of the contributing firms have reflected the Consumer Healthcare JV with Pfizer with varying completion dates

The firms included are: Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Morgan Stanley, Redburn, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Anoro 511 557 589 613 633 12
Arnuity 49 56 60 64 67 12
Incruse 300 341 373 397 418 12
Relvar/Breo 990 1,004 1,020 1,030 1,037 12
Trelegy 481 715 919 1,092 1,240 12
Ellipta portfolio 2,331 2,673 2,961 3,197 3,396 12
Nucala 749 900 995 1,072 1,125 12
Total Respiratory 3,080 3,573 3,957 4,269 4,521 12
             
Tivicay 1,664 1,677 1,652 1,615 1,581 11
Triumeq 2,550 2,429 2,303 2,201 2,115 11
Juluca 364 500 593 665 714 10
Dovato 63 259 464 656 789 10
Dolutegravir based regimens 4,641 4,871 5,019 5,145 5,218 12
Cabotegravir +/- rilpivirine 1 64 183 303 432 11
fostemsavir - 24 86 142 199 11
Epzicom/Kivexa 79 60 50 41 36 12
HIV 4,875 5,150 5,433 5,691 5,920 12
             
Benylsta 576 655 714 764 778 12
             
Zejula 246 403 544 714 876 12
             
Advair (US) 493 262 190 159 135 11
Seretide (ex US) 1,200 1,087 974 882 801 11
Seretide/Advair 1,693 1,349 1,164 1,041 936 12
Flixotide/Flovent 539 507 475 448 424 12
Ventolin 934 805 749 719 694 12
Avamys/Veramyst 330 348 355 358 326 12
Established Respiratory 3,773 3,279 3,005 2,819 2,624 12
Other Established Pharmaceuticals 4,907 4,721 4,490 4,285 4,074 12
Established Pharmaceuticals 8,680 8,000 7,495 7,104 6,698 12
             
belantamab mafodotin (GSK'916 BCMA) - 74 210 343 505 12
dostarlimab - 20 65 108 158 9
daprodustat - 2 35 90 174 11
             
Pharmaceuticals 17,460 17,875 18,454 19,184 19,954 12

The firms included are: Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Morgan Stanley, Redburn, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Bexsero 670 739 790 831 864 12
Menveo 251 267 279 292 304 12
Fluarix/Flulaval 558 582 599 616 632 12
Shingrix 1,524 1,803 2,067 2,400 2,707 12
Boostrix 575 597 610 621 632 12
Cervarix 125 130 135 139 141 12
Hepatitis 883 913 937 958 976 12
Infanrix, Pediarix 700 714 721 729 737 12
Rotarix 546 568 578 589 600 12
Synflorix 447 455 457 458 459 12
Vaccines 6,890 7,397 7,822 8,314 8,770 12

The firms included are: Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Morgan Stanley, Redburn, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Wellness (incl. Pfizer OTC) 5,093 7,047 7,253 7,476 7,703 11
Oral health 2,624 2,746 2,847 2,953 3,060 11
Nutrition 661 109 112 115 119 11
Skin Health 568 574 584 594 606 11
Consumer Health* 8,946 10,476 10,797 11,138 11,488 12

*All of the contributing firms have reflected the Consumer Healthcare JV with Pfizer with varying completion dates

The firms included are: Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, Exane, Jefferies, JP Morgan, Morgan Stanley, Redburn, Wolfe Research

Back to top